Psychiatr. praxi. 2020;21(2):62-64 | DOI: 10.36290/psy.2020.011

Residual symptoms of depression and their importance in common clinical practice

prof. MUDr. Eva Češková, CSc.1,2,3
1 Psychiatrická klinika LF MU a FN Brno
2 KNP LF Univerzity Ostrava
3 Oddělení psychiatrie, FN Ostrava

Residual symptoms in depressive disorder and their importance in common clinical praxis Residual symptoms are common, and they may occur even in patients fulfilling criteria for remission. Residual symptoms are associated with aworse outcome; therefor they should be identified, distinguished from side effects and treated as soon as possible. The treatment depends on the prevailing residual symptom. Although in average the available antidepressants do not differ in efficacy there are differences in the rate of influencing individual residual symptoms. The treatment strategy includes changing to another antidepressant, adjunctive medication and combination of antidepressants.

Keywords: depression, residual symptoms, outcome, treatment.

Published: June 29, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Residual symptoms of depression and their importance in common clinical practice. Psychiatr. praxi. 2020;21(2):62-64. doi: 10.36290/psy.2020.011.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Patten SB, Williams JVA, Lavorato DH, et al. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can J Psychiatry. 2015; 60(1): 23-30. Go to original source... Go to PubMed...
    2. Formanek T, Kagström A, Cermakova P, et al. Prevalence of mental disorders and associated disability: Results from the cross‑sectional CZEch mental health Study (CZEMS). Eur Psychiatry. 2019; 60-66. Go to original source...
    3. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010; 40(1): 41-50. Go to original source... Go to PubMed...
    4. Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety 2011; 28: 137-144. Go to original source... Go to PubMed...
    5. Romera I, Perez V, Ciudad A, et al. Residual symptoms and functioning in depression does the type of residual symptom matter? A post‑hoc analysis. BMC Psychiatry 2013: 13: 51-61. Go to original source...
    6. Nierenberg AA, Keefe BR, Leslie VC et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60: 221-225. Go to original source... Go to PubMed...
    7. Nil R, Lütolf S, Seifritz E Residual symptoms and functionality in depressed outpatients: A one‑year observational study in Switzerland with escitalopram. J Affect Disorder 2016; 197: 245-250. Go to original source... Go to PubMed...
    8. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995; 25: 1171-1180. Go to original source... Go to PubMed...
    9. Nierenberg AA: Residual Symptoms in Depression: Prevalence and Impact. J Clin Psych. 2015; 76(11): e1480. Go to original source...
    10. Maeshima H, Baba H, Satomur E et al. Residual memory impairment in remitted depression may be a predictive factor for recurrence. J Clin Psych. 2016;77: 247-251. Go to original source... Go to PubMed...
    11. Woo JM, Jeon HJ, Noh E, et al. Importance of remission and residual somatic symptoms in health‑related quality of life among outpatients with major depressive disorder: a cross‑sectional study. Health Qual Life Outcomes 2014;12: 188. Go to original source... Go to PubMed...
    12. Montgomery SA, Asberg, M.A. new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979; 134: 382-389. Go to original source... Go to PubMed...
    13. Hamilto, M.A. rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23, 56-62. Go to original source...
    14. Reilly TJ, MacGillivray SA, Reid IC, Cameron IM. Psychometric properties of the 16-item Quick Inventory of Depressive Symptomatology: a systematic review and meta‑analysis. J Psychiatr Res. 2015; 60: 132-140. Go to original source... Go to PubMed...
    15. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16: 606-613. Go to original source...
    16. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale: A procedure for measuring overall severity of psychiatric disturbance Arch. gen. Psychiatry 1976; 33: 766-771. Go to original source... Go to PubMed...
    17. McIntyre RS, Best MW, Bowie ChR et al. The THINC‑Integrated Tool (THINC‑it) screening assessment for cognitive dysfunction: Validation in patients with major depressive disorder. J Clin Psychiatry 2017; 78: 873-881. Go to original source...
    18. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004; 65: 959-965. Go to original source...
    19. Freeman MP, Fisher L, Clain A, et al. Differentiating residual symptoms of depression from adverse events among patients initiating treatment with an antidepressant. Ann Clin Psychiatry 2017; 29(1): 28-34. Go to PubMed...
    20. Uchida H, Yamawaki S, Bahk WM, Jon DI. Neuroscience‑based Nomenclature (NbN) for Clinical Psychopharmacology and Neuroscience. Clin Psychopharmacol Neurosci. 2016; 14(2): 115-116. Go to original source... Go to PubMed...
    21. Ustohal L. Nomenklatura založená na neurovědách 2 (NbN-2). Psychiatrie 2018; 22 (4): 204-208.
    22. Blier P. Neurotransmitter targeting in the treatment of depression. Clin Psychiatry 2013; 74 (suppl 2): 14-18. Go to original source...
    23. Ceskova E. Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants Expert Opin Pharmacother. 2016; 17(14): 1835-1837. Go to original source... Go to PubMed...
    24. Ceskova E, Sedova M, Kellnerova R, Starobova O. Once‑a day trazodone in the treatment of depression in routine clinical practice. Pharmacology 2018; 102(3-4): 206-212. Go to original source...
    25. Citrome LL, McIntyre RS, Manning JS, McIntosh D. Activating and sedating properties of medications used for the treatment of major depressive disorder and their effect on patient functioning. J Clin Psychiatry 2019; 80: lu18052ah1. Go to original source...
    26. Vitali M, Tedeschini E, Mistretta M, et al. Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety. J Clin Psychopharmacol. 2013; 33(1): 95-98. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.